Author: Pastick, Katelyn A; Nicol, Melanie R; Smyth, Elizabeth; Zash, Rebecca; Boulware, David R; Rajasingham, Radha; McDonald, Emily G
Title: A Systematic Review of Treatment and Outcomes of Pregnant Women with COVID-19 – A Call for Clinical Trials Cord-id: kve6fa49 Document date: 2020_8_13
ID: kve6fa49
Snippet: BACKGROUND: Data pertaining to COVID-19 in pregnancy are limited; to better inform clinicians, we collated data from COVID-19 cases in pregnancy and summarized clinical trials enrolling this population. METHODS: We performed a systematic literature review of PubMed/MEDLINE to identify cases of COVID-19 in pregnancy or the postpartum period and associated outcomes. We then evaluated the proportion of COVID-19 clinical trials (from Clinicaltrials.gov) excluding pregnant or breastfeeding persons (b
Document: BACKGROUND: Data pertaining to COVID-19 in pregnancy are limited; to better inform clinicians, we collated data from COVID-19 cases in pregnancy and summarized clinical trials enrolling this population. METHODS: We performed a systematic literature review of PubMed/MEDLINE to identify cases of COVID-19 in pregnancy or the postpartum period and associated outcomes. We then evaluated the proportion of COVID-19 clinical trials (from Clinicaltrials.gov) excluding pregnant or breastfeeding persons (both through June 29(th), 2020). RESULTS: We identified 11,308 published cases of COVID-19 in pregnancy. Of those reporting disease severity, 21% (416/1999) were severe/critical. Maternal and neonatal survival were reassuring (98% [10437/10597] and 99% [1155/1163], respectively). Neonatal disease was rare with only 41 possible cases of infection reported in the literature. Of 2351 ongoing COVID-19 therapeutic clinical trials, 1282 were enrolling persons of reproductive age and 65% (829/1282) excluded pregnant persons. Pregnancy was an exclusion criterion for 69% (75/109) of chloroquine/hydroxychloroquine, 80% (28/35) of lopinavir/ritonavir, and 48% (44/91) of convalescent plasma studies. We identified 48 actively recruiting or completed drug trials reporting inclusion of this population. CONCLUSIONS: There are limited published reports of COVID-19 in pregnancy despite more than 14 million cases worldwide. To date, clinical outcomes appear reassuring, but data related to important long-term outcomes are missing or not yet reported. The large number of clinical trials excluding pregnant persons, despite interventions with safety data in pregnancy, is concerning. In addition to observational cohort studies, pregnancy specific adaptive clinical trials could be designed to identify safe and effective treatments.
Search related documents:
Co phrase search for related documents- actual indication and acute respiratory syndrome: 1
- acute respiratory syndrome and adaptive clinical trial: 1, 2
- acute respiratory syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir ritonavir hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive clinical trial and lopinavir ritonavir: 1, 2
- adaptive clinical trial and lopinavir ritonavir hydroxychloroquine: 1
- long term follow and lopinavir ritonavir: 1
- long term follow and lopinavir ritonavir hydroxychloroquine: 1
- long term follow and lupus erythematosus: 1, 2, 3
- lopinavir ritonavir and lupus erythematosus: 1, 2, 3, 4
- lopinavir ritonavir hydroxychloroquine and lupus erythematosus: 1, 2
Co phrase search for related documents, hyperlinks ordered by date